Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Conditions
Keywords
advanced adult primary liver cancer, unresectable gallbladder cancer, unresectable extrahepatic bile duct cancer, adult primary cholangiocellular carcinoma
Brief summary
RATIONALE: Drugs used in chemotherapy such as gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining gemcitabine with pemetrexed disodium may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when given together with pemetrexed disodium to see how well it works in treating patients with unresectable or metastatic biliary tract or gallbladder cancer.
Detailed description
OBJECTIVES: * Determine the maximum tolerated dose of gemcitabine when administered with pemetrexed disodium in patients with unresectable or metastatic biliary tract or gallbladder cancer. (Phase I closed to accrual as of Oct. 2005.) * Determine the 6-month survival rate of patients treated with this regimen. * Determine the best objective tumor response rate and duration of best objective tumor response in patients treated with this regimen. * Determine the time to progression and overall survival of patients treated with this regimen. * Determine the toxic effects of this regimen in these patients. * Determine the individual patient variation in toxicity of and/or response to this regimen due to genetic differences in proteins involved in drug response in these patients. OUTLINE: This is a multicenter phase I dose-escalation study of gemcitabine followed by a phase II study. * Phase I: Patients receive pemetrexed disodium IV over 10 minutes and gemcitabine IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity (phase I closed to accrual as of October 2005). Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. * Phase II: Patients receive pemetrexed disodium as in phase I and gemcitabine at the recommended phase II dose. Patients are followed every 3 months for 1 year and then every 6 months for 4 years. PROJECTED ACCRUAL: A total of 85 patients will be accrued for this study.
Interventions
DRUGgemcitabine hydrochloride
DRUGpemetrexed disodium
Sponsors
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* One of the following histologically or cytologically confirmed cancers not amenable to treatment with combined chemotherapy and radiotherapy: * Biliary tract (intrahepatic, extrahepatic, or ampulla of Vater) carcinoma * Gallbladder carcinoma * Unresectable or metastatic disease * No CNS metastases * Prior brain metastases treated with surgery or radiosurgery allowed provided treatment was completed at least 4 weeks ago and there is no evidence of CNS progression * No clinically significant pericardial or pleural effusion or ascites unless able to be drained before study entry * Performance status - ECOG 0-2 * At least 3 months * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 3 times upper limit of normal (ULN) * AST no greater than 5 times ULN * Creatinine no greater than 1.5 times ULN * Creatinine clearance at least 45 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer * Able to tolerate folic acid, corticosteroids, or cyanocobalamin supplements * More than 4 weeks since prior biologic or immunologic therapy * No prior biologic or immunologic therapy for metastatic disease * No concurrent immunotherapy * No concurrent colony-stimulating factors during course 1 * No prior chemotherapy for metastatic disease * No prior gemcitabine * Prior chemoembolization allowed provided the following are true: * At least 4 weeks since prior chemoembolization * Evidence of new tumor growth since therapy * At least 6 months since prior chemotherapy used as a radiosensitizer (in adjuvant setting or for locally advanced disease) * No other concurrent chemotherapy * Prior radiofrequency ablation allowed provided the following are true: * At least 4 weeks since prior radiofrequency ablation * Evidence of new tumor growth since therapy * No prior radiotherapy to 25% or more of the bone marrow * More than 4 weeks since prior radiotherapy * No concurrent radiotherapy * Prior embolization allowed provided the following are true: * At least 4 weeks since prior embolization * Evidence of new tumor growth since therapy * No prior pemetrexed disodium * No aspirin or nonsteroidal anti-inflammatory drugs for at least 2 days (5 days for long-acting agents \[e.g., piroxicam\]) before, during, and for at least 2 days after administration of pemetrexed disodium * No concurrent cyclo-oxygenase-2 inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival after 6 months of treatment | Up to 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Response as assessed by RECIST criteria every 8-16 weeks | Up to 16 weeks |
| Toxicity as assessed by CTC v3 every 4 weeks | Up to 4 weeks |
Countries
United States
Outcome results
None listed